APP
attention us:
Technical Service
Contact information
Welcome to call the service hotline

Hotline1:400-003-5255

Hotline2:010-87529591

Cancer Genomics Research

Location>Home>Technical Service>Cancer Genomics Research

Cancer Genomics Research

Product Overview
Cancer , also known as a malignant tumor or malignant neoplasm, is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Genetic alterations is the fundamental cause of cancer. Therefore researches on cancer genomics can reveal the molecular mechanisms of cancerinogenesis and identify potential targets for therapy.

Recently, tumor driver genes are recognized as the major “engine” that drive tumorigenesis. Mygenostics Tumor Driver gene panel and Mouse Tumor Driver Gene panel conclude all known tumor driver genes, which allow researchers to scan 277 human tumor driver genes or 259 mouse tumor driver gene through Next-generation-sequencing platforms in different types of samples efficiently.

In addition, Mygenostics cancer genomics research system make the sequencing of circulating tumor DNA (ctDNA) precisely with very high sensitivity. CtDNA analysis has already become a very effective tool for cancer researchers. Based on the tumor driven gene capture and ctDNA analysis, Mygenostics has also developed the “Oncocare system” which can be applied to monitor tumor load simply through plasma sample during the cancer treatment.

System Workflow
     OncoCare workflow


Technical characteristics
277 human tumor driver genes derive from “Cancer Genome landscapes” published by Bert Vogelstein and “Mutational landscape and significance across 12 major cancer types” of The Cancer Genome Atlas.

Sequencing strategy
180~280bp insert DNA library
Hiseq platform, paired-end 150bp

Sequencing depth
Average effective sequencing depth above 1000X

Data Analysis
SNP and Indel calls, Gene fusion, gene duplication and deletion 
Customized analysis is also available 

Sample Requirements:
For fresh sample: ≥ 1.0 μg (a minimum of 200 ng can be accepted with risk)
For FFPE sample: ≥ 1.5 μg
DNA concentration: ≥ 20 ng/μl
DNA Volume: ≥ 10 μl
OD260/280 = 1.8 - 2.0 without degradation or RNA contamination
Project time cycle
30 working days after verification of sample quality (without data analysis)
Additional 5~15 working days for data analysis

Case review
Reference